Neutral
●
PRNewsWire
●
6 months ago
With acquisition of Japan rights, Nuvation Bio now has global development and commercialization rights for safusidenib Agreement provides Nuvation Bio ownership of global clinical development program, inclusive of clinical trials, past and current data generation, and future publications NEW YORK, April 1, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on...